{"id":"W1516639348","doi":"10.1158/1538-7445.sabcs14-s6-04","title":"Abstract S6-04: Fulvestrant 500 mg versus anastrozole as first-line treatment for advanced breast cancer: Overall survival from the Phase II ‘FIRST’ study","year":2015,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"ca_institutions":"AstraZeneca (Canada)","funders":"","keywords":"Fulvestrant; Anastrozole; Medicine; Hazard ratio; Internal medicine; Clinical endpoint; Metastatic breast cancer; Oncology; Breast cancer; Phases of clinical research; Cancer; Confidence interval; Tamoxifen; Randomized controlled trial; Clinical trial","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003965504,0.001664932,0.002881123,0.0007046463,0.0003147256,0.001359256,0.001157568,0.002084142,0.005769834],"category_scores_gemma":[0.002157235,0.0006174775,0.003851291,0.0004640192,0.0007920989,0.001003195,0.0004687137,0.004206244,0.001091302],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009075358,"about_ca_system_score_gemma":0.001334664,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006013062,"about_ca_topic_score_gemma":0.001310088,"domain_scores_codex":[0.9989807,0.0006886323,0.00005207484,0.00009408964,0.00008028802,0.0001042545],"domain_scores_gemma":[0.9981263,0.0005208757,0.0004245051,0.0001688053,0.0001132389,0.0006461399],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9115037,0.01860201,0.003181329,0.001086562,0.003675639,0.0001184007,0.00008089565,0.00115018,0.008207817,0.0001107145,0.004128443,0.04815421],"study_design_scores_gemma":[0.6963192,0.2846544,0.01071227,0.0001011471,0.00235799,0.0001633845,0.0000269683,0.0006947019,0.00219347,0.0001291057,0.00262172,0.00002567641],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9713967,0.01587098,0.0007499562,0.002276464,0.0006632431,0.002039399,0.004215188,0.0001951838,0.00259291],"genre_scores_gemma":[0.9725823,0.007748557,0.001659755,0.002625838,0.001298329,0.002008032,0.007329731,0.00006742118,0.004680093],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005769834,"threshold_uncertainty_score":0.02097189,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1979236632696527,"score_gpt":0.4825408365740193,"score_spread":0.2846171733043665,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}